Decoding Antimicrobial Resistance: Fusing Biologic Acumen and Computational Virtuosity for Paradigmatic Drug Innovation

Abstract

BackgroundAntimicrobial resistance (AMR) poses a critical threat to global health, necessitating innovative strategies to identify druggable targets and develop effective therapies. Traditional approaches often fail to address the rapid evolution of resistance mechanisms, particularly in high-priority pathogens. This study integrates AI-driven gene prioritization with nanotechnology to combat multidrug-resistant bacterial infections. MethodsA dual-axis strategy was made to formulate genetic algorithm selection for gene centrality, conservation, interaction networks that has been effectively used to predict draggability scores for AMR genes (blaNDM-1, mcr-1). Hydroxyapatite-alginate-chitosan nano capsules were synthesized for pH-responsive ciprofloxacin delivery. Molecular docking validated ligand-target compatibility, while dynamic light scattering (DLS) and SEM characterized nanoparticle morphology (100-200 nm). In vitro drug release kinetics were assessed over 48 hours. ResultsblaNDM-1 showed an (draggability score: 0.92) and mcr-1 (0.89) that have been emerged as top targets with activity against both E. coli and Pseudomonas aeruginosa, due to their enzymatic roles in {beta}-lactam and colistin resistance. Uniform nano capsules (150 {+/-} 25 nm) demonstrated sustained ciprofloxacin release (75% cumulative release at 24 h). Docking confirmed stable binding of ciprofloxacin to active sites of target proteins (hydrogen bonds [≤]2.0 [A]), supporting inhibitory potential. ConclusionsThese findings indicate computational and experimental approaches to address AMR. The AI-nano therapy pipeline identified high-value targets and validated nanoparticle-based drug delivery, achieving a 6-log reduction in bacterial load in vitro. Future work will focus on in vivo validation and clinical translation.